Magle Chemoswed Holding AB
STO:MAGLE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Magle Chemoswed Holding AB
Revenue
Magle Chemoswed Holding AB
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Magle Chemoswed Holding AB
STO:MAGLE
|
Revenue
kr282.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
AddLife AB
STO:ALIF B
|
Revenue
kr10.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
BICO Group AB
STO:BICO
|
Revenue
kr1.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
Revenue
kr2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
G
|
Genovis AB
STO:GENO
|
Revenue
kr128.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
26%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Revenue
kr2.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
21%
|
CAGR 10-Years
9%
|
|
Magle Chemoswed Holding AB
Glance View
Magle Chemoswed Holding AB engages in the provision of contract development and manufacturing services to the pharmaceutical and medical device industry. The company is headquartered in Malmo, Skane. The company went IPO on 2020-06-30. The firm's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.
See Also
What is Magle Chemoswed Holding AB's Revenue?
Revenue
282.9m
SEK
Based on the financial report for Dec 31, 2025, Magle Chemoswed Holding AB's Revenue amounts to 282.9m SEK.
What is Magle Chemoswed Holding AB's Revenue growth rate?
Revenue CAGR 5Y
15%
Over the last year, the Revenue growth was 20%. The average annual Revenue growth rates for Magle Chemoswed Holding AB have been 25% over the past three years , 15% over the past five years .
